Expertise in
4
conditions

Dr. Thomas W. O'brien

Kissimmee, FL
Expertise in
4
conditions
Specialties:Pulmonary Medicine | Intensive Care Medicine
Accepting New Patients
Expertise in
4
conditions
OverviewInsuranceLocationsClinical Research

Overview

Thomas O'brien is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Kissimmee, Florida. Dr. O'brien is highly rated in 4 conditions, according to our data. His top areas of expertise are Asthma, Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, and Asthma in Children. Dr. O'brien is currently accepting new patients.

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Critical Care Medicine in FL
Languages Spoken
English
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Health First
  •  Health Options
  •  Oscar
  •  Humana
  •  Florida Blue

Locations

1121 N Central Ave, Suite B, Kissimmee, FL 34741
407-933-1221

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: SUVN-G3031
Study Phase: Phase 2
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: December 17, 2024
Intervention Type: Drug, Biological
Study Drug: GSK3511294
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR
Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR
Enrollment Status: Completed
Publish Date: January 30, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Completed
Publish Date: September 08, 2022
Intervention Type: Other, Drug
Study Drug: KD025
Study Phase: Phase 2
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Drug, Device
Study Phase: Phase 4
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
View 8 Less Clinical Trials
Similar Doctors
Expertise in
21
conditions
Dr. Fortune O. Alabi
Intensive Care Medicine | Pulmonary Medicine
Expertise in
21
conditions
Dr. Fortune O. Alabi
Intensive Care Medicine | Pulmonary Medicine

Florida Lung Asthma And Sleep Specialists

3480 Polynesian Isle Blvd, 
Kissimmee, FL 
 (5.8 mi)
407-507-2615
Languages Spoken:
English, Urdu, Yoruba
See accepted insurances
Accepting New Patients
Offers Telehealth

Fortune Alabi is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Kissimmee, Florida. Dr. Alabi is highly rated in 21 conditions, according to our data. His top areas of expertise are Asthma, Lung Metastases, Pleural Effusion, and Asthma in Children. Dr. Alabi is currently accepting new patients.

Expertise in
31
conditions
Dr. Ahmad S. Jalloul
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Expertise in
31
conditions
Dr. Ahmad S. Jalloul
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
2762 Dora Ave, 
Tavares, FL 
 (39.9 mi)
352-404-5968
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ahmad Jalloul is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Tavares, Florida. Dr. Jalloul is highly rated in 31 conditions, according to our data. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Asthma in Children, Asthma, and Advanced Bronchoscopy. Dr. Jalloul is currently accepting new patients.

Expertise in
14
conditions
Dr. Fred C. Umeh
Intensive Care Medicine | Pulmonary Medicine
Expertise in
14
conditions
Dr. Fred C. Umeh
Intensive Care Medicine | Pulmonary Medicine

Florida Lung Asthma And Sleep Specialists

3480 Polynesian Isle Blvd, 
Kissimmee, FL 
 (5.8 mi)
407-507-2615
Languages Spoken:
English, Igbo, Spanish, Urdu, Yoruba
See accepted insurances
Accepting New Patients
Offers Telehealth

Fred Umeh is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Kissimmee, Florida. Dr. Umeh is highly rated in 14 conditions, according to our data. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Hospital-Acquired Pneumonia, and Atypical Pneumonia. Dr. Umeh is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile